This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: PFE's COVID Jab Full Approval by FDA, JNJ's Booster Data
by Kinjel Shah
FDA approves Pfizer's (PFE) BLA for COVID-19 vaccine, Comirnaty. J&J (JNJ) released data supporting use of the booster shot.
FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study
by Zacks Equity Research
FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.
AstraZeneca's (AZN) Rare Disease Study Meets Primary Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study evaluating ALXN1840 for Wilson disease achieves primary endpoint. The company also receives approval in Japan for Forxiga to treat chronic kidney disease.
Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK
by Zacks Equity Research
Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
by Zacks Equity Research
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
AstraZeneca (AZN) Stops Phase III Study on Ultomiris for ALS
by Zacks Equity Research
AstraZeneca (AZN) stops the phase III CHAMPION-ALS study on Ultomiris for treating adults with amyotrophic lateral sclerosis, following a recommendation from the Independent Data Monitoring Committee.
Lilly's (LLY) Jardiance Gets FDA Approval for Heart Failure
by Zacks Equity Research
Lilly's (LLY) Jardiance gets FDA approval for heart failure with reduced ejection fraction (HFrEF), based on data from the phase III EMPEROR-Reduced study
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
by Zacks Equity Research
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, AstraZeneca, Keurig Dr Pepper and Phillips 66
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, AstraZeneca, Keurig Dr Pepper and Phillips 66
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Research Reports for Microsoft, JPMorgan & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), JPMorgan Chase & Co. (JPM), and AstraZeneca PLC (AZN).
Merck's (MRK) VHL-Linked Tumor Drug Welireg Gets FDA Nod
by Zacks Equity Research
Merck's (MRK) Welireg (belzutifan) is the first and only systemic therapy approved for treating patients with certain types of von Hippel-Lindau (VHL) disease-associated tumors.
Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA
by Zacks Equity Research
Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.
Pharma Stock Roundup: FDA Nod for SNY's Pompe Drug & New Use of MRK's Keytruda
by Kinjel Shah
FDA approves Sanofi's (SNY) Nexviazyme for late-onset Pompe disease and Merck's (MRK) Keytruda plus Lenvima for first-line kidney cancer.
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
Do Options Traders Know Something About AstraZeneca (AZN) Stock We Don't?
by Aditi Saraogi
Investors need to pay close attention to for AstraZeneca (AZN) stock based on the movements in the options market lately.
Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss for the second quarter of 2021. Revenues too miss expectations.
Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval
by Zacks Equity Research
The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.
Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates
by Kinjel Shah
Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.
Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.
Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.